214 related articles for article (PubMed ID: 27480848)
1. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
Torrens G; Cabot G; Ocampo-Sosa AA; Conejo MC; Zamorano L; Navarro F; Pascual Á; Martínez-Martínez L; Oliver A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6407-10. PubMed ID: 27480848
[TBL] [Abstract][Full Text] [Related]
2. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
[TBL] [Abstract][Full Text] [Related]
8. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
[No Abstract] [Full Text] [Related]
9. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
10. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Keepers TR; Gomez M; Celeri C; Nichols WW; Krause KM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5297-305. PubMed ID: 24957838
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
[TBL] [Abstract][Full Text] [Related]
12. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
[TBL] [Abstract][Full Text] [Related]
14. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Fraile-Ribot PA; Zamorano L; Orellana R; Del Barrio-Tofiño E; Sánchez-Diener I; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740559
[TBL] [Abstract][Full Text] [Related]
15. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
17. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F
Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111
[TBL] [Abstract][Full Text] [Related]
20. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
